Indevus Pharmaceuticals (NasdaqNM:IDEV) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Indevus Pharmaceuticals (NasdaqNM:IDEV)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Sidney Street who wrote (17)	5/28/2004 1:45:41 PM
From: Greg Rich	of 78

UPDATE 1-FDA approves Indevus's overactive bladder drug May 28, 2004 1:02:00 PM ET (Updates with details) NEW YORK, May 28 (Reuters) - Indevus Pharmaceuticals Inc. (IDEV) said on Friday that U.S. regulators approved its experimental drug for overactive bladder. The U.S. Food and Drug Administration approved the drug, Sanctura, which will be co-promoted by the Croatian drug maker Pliva through its specialty U.S. subsidiary Odyssey Pharmaceuticals Inc. The drug is expected to be launched during the third quarter. The drug belongs to a class known as muscarinic receptor antagonists, which relax smooth muscle tissue in the bladder and reduce bladder contractions, the cause of overactive bladder. It will compete in a market estimated to be worth $1.1 billion in 2004. The drug's main side effects are dry mouth and constipation. It is already marketed in Europe. Lexington, Massachusetts-based Indevus's shares rose 48 cents, or 6 percent, to $8.90 in early afternoon trading on Nasdaq. REUTERS © 2004 Reuters

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next